Last reviewed · How we verify
MC0518
MC0518 is a histone deacetylase (HDAC) inhibitor that promotes differentiation and apoptosis of myelodysplastic syndrome cells.
MC0518 is a histone deacetylase (HDAC) inhibitor that promotes differentiation and apoptosis of myelodysplastic syndrome cells. Used for Myelodysplastic syndrome (MDS).
At a glance
| Generic name | MC0518 |
|---|---|
| Sponsor | medac GmbH |
| Drug class | Histone deacetylase (HDAC) inhibitor |
| Target | Histone deacetylase (HDAC) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MC0518 inhibits histone deacetylase enzymes, leading to increased histone acetylation and altered gene expression in hematopoietic cells. This mechanism promotes differentiation of myelodysplastic cells and induces apoptosis, reducing abnormal cell proliferation. The drug is designed to restore normal hematopoietic differentiation in MDS patients.
Approved indications
- Myelodysplastic syndrome (MDS)
Common side effects
- Thrombocytopenia
- Anemia
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease (PHASE2)
- Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MC0518 CI brief — competitive landscape report
- MC0518 updates RSS · CI watch RSS
- medac GmbH portfolio CI